metformin has been researched along with Centriacinar Emphysema in 3 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| " One possible modulator of ENaC is AMP-activated protein kinase (AMPK), a key molecule that controls a wide variety of cellular signals; however, little is known about whether metformin, a clinically available AMPK activator, has a protective role against ENaC-associated chronic pulmonary phenotypes, such as emphysema and pulmonary dysfunction." | 4.12 | Metformin suppresses epithelial sodium channel hyperactivation and its associated phenotypes in a mouse model of obstructive lung diseases. ( Eto, Y; Fujikawa, H; Hayashi, M; Kai, H; Kamei, S; Kawakami, T; Kishimoto, T; Maruta, K; Nakashima, R; Nasu, A; Nohara, H; Shuto, T; Suico, MA; Takahashi, N; Ueno-Shuto, K, 2022) |
| "We studied whether in patients with COPD the use of metformin for diabetes treatment was linked to a pattern of lung function decline consistent with the hypothesis of anti-aging effects of metformin." | 1.72 | Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment. ( Alter, P; Andreas, S; Bals, R; Behr, J; Frankenberger, M; Jörres, RA; Kahnert, K; Kellerer, C; Lehmann, M; Lucke, T; Lutter, JI; Seissler, J; Trudzinski, FC; Vogelmeier, CF; Watz, H; Welte, T; Yildirim, Ö, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kahnert, K | 1 |
| Andreas, S | 1 |
| Kellerer, C | 1 |
| Lutter, JI | 1 |
| Lucke, T | 1 |
| Yildirim, Ö | 1 |
| Lehmann, M | 1 |
| Seissler, J | 1 |
| Behr, J | 1 |
| Frankenberger, M | 1 |
| Bals, R | 1 |
| Watz, H | 1 |
| Welte, T | 1 |
| Trudzinski, FC | 1 |
| Vogelmeier, CF | 1 |
| Alter, P | 1 |
| Jörres, RA | 1 |
| Nakashima, R | 1 |
| Nohara, H | 1 |
| Takahashi, N | 1 |
| Nasu, A | 1 |
| Hayashi, M | 1 |
| Kishimoto, T | 1 |
| Kamei, S | 1 |
| Fujikawa, H | 1 |
| Maruta, K | 1 |
| Kawakami, T | 1 |
| Eto, Y | 1 |
| Ueno-Shuto, K | 1 |
| Suico, MA | 1 |
| Kai, H | 1 |
| Shuto, T | 1 |
| Petrache, I | 1 |
| Serban, KA | 1 |
3 other studies available for metformin and Centriacinar Emphysema
| Article | Year |
|---|---|
Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment.
Topics: Age Factors; Aged; Body Mass Index; Cohort Studies; Diabetes Mellitus; Female; Forced Expiratory Vol | 2022 |
Metformin suppresses epithelial sodium channel hyperactivation and its associated phenotypes in a mouse model of obstructive lung diseases.
Topics: AMP-Activated Protein Kinases; Animals; Disease Models, Animal; Emphysema; Epithelial Sodium Channel | 2022 |
Can Metformin Downshift the Gears of Aging to Slow Emphysema Progression?
Topics: Aging; Emphysema; Humans; Metformin; Pulmonary Emphysema | 2021 |